Onconetix (NASDAQ:ONCO) Trading Down 24.9% – Should You Sell?

Onconetix, Inc. (NASDAQ:ONCO)’s stock price traded down 24.9% on Friday . The company traded as low as $4.65 and last traded at $4.73. 302,077 shares were traded during mid-day trading, an increase of 193% from the average session volume of 102,989 shares. The stock had previously closed at $6.30.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Onconetix to a “hold” rating in a report on Saturday.

Onconetix Price Performance

The business’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $25.39.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings results on Thursday, June 12th. The company reported $21.25 earnings per share for the quarter. The firm had revenue of $0.10 million during the quarter.

Institutional Trading of Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Geode Capital Management LLC bought a new position in Onconetix, Inc. (NASDAQ:ONCO) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 55,418 shares of the company’s stock, valued at approximately $35,000. Geode Capital Management LLC owned approximately 0.67% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.